Libradin

Barnidipine, the active ingredient in Libradin, is a calcium channel blocker presented as an oral tablet for oral administration. It selectively inhibits L‑type calcium channels in vascular smooth muscle, leading to vasodilation and a reduction in systemic blood pressure. The medication is prescribed for the treatment of hypertension in adult patients.

GNH USA supplies Libradin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent product quality and regulatory compliance across European and global markets.

Barnidipine, marketed as Libradin, is employed to lower elevated systemic arterial pressure by causing vasodilation of peripheral blood vessels, thereby improving cardiovascular outcomes in patients with high blood pressure.

- Hypertension: produces a dose‑dependent decrease in both systolic and diastolic blood pressure, facilitating attainment of target levels recommended by clinical guidelines for adult patients. - Essential (primary) hypertension: offers sustained blood pressure control over 24 hours, contributing to reduced risk of stroke, myocardial infarction and other hypertension‑related complications.

Barnidipine may be associated with several adverse reactions